Renaissance Technologies
ACAD icon

Renaissance Technologies’s Acadia Pharmaceuticals ACAD Stock Holding History

Renaissance Technologies’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4M Sell
1,282,596
-441,600
-26% -$9.72M 0.04% 500
2026
Q1 		$38.4M Buy
1,724,196
+191,600
+13% +$4.58M 0.06% 404
2025
Q4 		$40.9M Buy
1,532,596
+83,063
+6% +$1.98M 0.06% 344
2025
Q3 		$30.9M Sell
1,449,533
-98,199
-6% -$2.32M 0.04% 540
2025
Q2 		$33.4M Buy
1,547,732
+70,699
+5% +$1.31M 0.04% 496
2025
Q1 		$24.5M Buy
1,477,033
+250,500
+20% +$4.55M 0.04% 583
2024
Q4 		$22.5M Buy
1,226,533
+823,333
+204% +$13.3M 0.03% 613
2024
Q3 		$6.2M Sell
403,200
-72,800
-15% -$1.21M 0.01% 1308
2024
Q2 		$7.74M Sell
476,000
-97,800
-17% -$1.58M 0.01% 1068
2024
Q1 		$10.6M Buy
573,800
+389,800
+212% +$9.66M 0.02% 962
2023
Q4 		$5.76M Buy
+184,000
New +$4.39M 0.01% 1267
2023
Q3 		– Sell
-130,800
Closed -$3.13M – 3615
2023
Q2 		$3.13M Buy
130,800
+13,000
+11% +$289K ﹤0.01% 1705
2023
Q1 		$2.22M Sell
117,800
-197,900
-63% -$3.77M ﹤0.01% 1970
2022
Q4 		$5.03M Buy
315,700
+278,000
+737% +$4.35M 0.01% 1520
2022
Q3 		$617K Buy
+37,700
New +$611K ﹤0.01% 2800
2022
Q2 		– Sell
-14,500
Closed -$351K – 4177
2022
Q1 		$351K Buy
+14,500
New +$351K ﹤0.01% 3395
2021
Q2 		– Sell
-581,000
Closed -$15M – 3413
2021
Q1 		$15M Buy
581,000
+398,600
+219% +$17.5M 0.02% 946
2020
Q4 		$9.75M Sell
182,400
-87,100
-32% -$4.32M 0.01% 1189
2020
Q3 		$11.1M Buy
269,500
+157,300
+140% +$6.79M 0.01% 1062
2020
Q2 		$5.44M Buy
112,200
+51,400
+85% +$2.47M ﹤0.01% 1595
2020
Q1 		$2.57M Sell
60,800
-670,200
-92% -$27.6M ﹤0.01% 1925
2019
Q4 		$31.3M Buy
731,000
+645,200
+752% +$28.1M 0.02% 756
2019
Q3 		$3.09M Buy
+85,800
New +$2.6M ﹤0.01% 2049
2019
Q1 		– Sell
-597,800
Closed -$9.67M – 3420
2018
Q4 		$9.67M Buy
597,800
+425,500
+247% +$8.26M 0.01% 1328
2018
Q3 		$3.58M Sell
172,300
-50,900
-23% -$801K ﹤0.01% 1996
2018
Q2 		$3.41M Buy
+223,200
New +$3.98M ﹤0.01% 1999

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies's ACAD Position: Q2 2026 in Review

Renaissance Technologies reduced its Acadia Pharmaceuticals (ACAD) stake by 26% in Q2 2026, selling an estimated $9.72M and leaving 1,282,596 shares worth $32.4M. The position accounts for 0.04% of the portfolio, ranked #500.

Renaissance Technologies first reported a position in ACAD in Q2 2018 and has held it in 26 quarters since. The position peaked at $40.9M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Renaissance Technologies held 1,282,596 shares of Acadia Pharmaceuticals worth $32.4M as of Q2 2026.
  • Renaissance Technologies sold 441,600 Acadia Pharmaceuticals shares in Q2 2026, an estimated $9.72M.
  • Acadia Pharmaceuticals made up 0.04% of Renaissance Technologies's portfolio in Q2 2026, its #500 holding.
  • Renaissance Technologies first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 26 quarters since.
  • Renaissance Technologies's Acadia Pharmaceuticals position peaked at $40.9M in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.